Kisunla (donanemab-azbt) - Eli Lilly
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (clinicaltrials.gov) - Sep 25, 2026 - P4 | N=50 | Not yet recruiting | Sponsor: Eli Lilly and Company 
New P4 trial • Alzheimer's Disease • CNS Disorders
http://clinicaltrials.gov/ct2/show/NCT07838155
 
Sep 25, 2026
 
Prev Next